3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
CNS
1
Conditions
Ovarian Neoplasms
27
Fallopian Tube Neoplasms
9
Prostatic Neoplasms
8
Breast Neoplasms
8
Neoplasms
6
Pancreatic Neoplasms
5
Endometrial Neoplasms
5
Neoplasm Metastasis
4
Triple Negative Breast Neoplasms
3
Mesothelioma
3
Lung Neoplasms
3
Head and Neck Neoplasms
3
Glioblastoma
3
Carcinoma, Ovarian Epithelial
3
Squamous Cell Carcinoma of Head and Neck
2
Small Cell Lung Carcinoma
2
Recurrence
2
Mesothelioma, Malignant
2
Melanoma
2
Esophageal Neoplasms
2
Colorectal Neoplasms
2
Cholangiocarcinoma
2
Carcinoma, Renal Cell
2
Uveal Melanoma
1
Uterine Neoplasms
1
Uterine Cervical Neoplasms
1
Urologic Neoplasms
1
Urogenital Neoplasms
1
Thrombocytopenia
1
Stomach Neoplasms
1
Interventions
Temozolomide
37
Radiotherapy
20
Bevacizumab
14
Carboplatin
10
Magnetic Resonance Spectroscopy
9
Carmustine
9
antineoplaston AS 2-1
8
antineoplaston A10
8
Irinotecan
8
Filgrastim
7
Cyclophosphamide
6
Cisplatin
6
Etoposide
5
sargramostim
4
Vincristine
4
Thiotepa
4
Surgical Procedures, Operative
4
Specimen Handling
4
Radiation
4
Peripheral Blood Stem Cell Transplantation
4
Lomustine
4
Everolimus
4
Chemotherapy, Adjuvant
4
trametinib
3
aldesleukin
3
Topotecan
3
Thalidomide
3
Tamoxifen
3
Sunitinib
3
Procarbazine
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Astrocytoma
×
niraparib
×
Clear all
NCT05297864
2025-05-23
OU-SCC-PI-4G
University of Oklahoma
Phase 2
Terminated
15 enrolled
13 charts